Trials / Completed
CompletedNCT02412865
Quit4Baby Evaluation
Developing and Scaling a Text Messaging Tool to Help Pregnant Smokers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 505 (actual)
- Sponsor
- George Washington University · Academic / Other
- Sex
- Female
- Age
- 14 Years – 44 Years
- Healthy volunteers
- Accepted
Summary
The goal of this project is to evaluate the effectiveness (Phase II) of a text-based program to be called Quit4Baby to support smoking cessation efforts of pregnant women who smoke. In Phase II, Dr. Abroms will conduct a randomized clinical trial among 500 pregnant smokers who have been recruited from users of text4baby - the first large scale mobile health application in the United States. Developed and operated by Voxiva and Healthy Mothers, Healthy Babies (HMHB)-collaborators in this program -text4baby is a free national service that has enrolled more than 800,000 pregnant women and mothers of infants 0-1 nationwide and delivered more than 150 million health messages to them including messages encouraging them not to smoke during pregnancy and referring them to quit lines. Hypothesis 1: Pregnant smokers who receive quit4Baby + text4Baby will demonstrate higher levels of knowledge about the dangers of second hand smoke and the benefits of smoking cessation for mothers and their infants than text4baby only users. Hypothesis 2: Pregnant smokers who receive quit4baby + text4baby will report significantly higher rates of calling a quit line, discussions with their health provider and/or use of cessation counseling than those who receive Text4baby alone. Hypothesis 3: Pregnant smokers who receive quit4baby + text4baby will have significantly more favorable quitting outcomes compared with text4baby alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Quit4Baby | |
| BEHAVIORAL | Text4Baby |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-02-01
- First posted
- 2015-04-09
- Last updated
- 2016-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02412865. Inclusion in this directory is not an endorsement.